Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Guwahati, Assam, India.
Phytother Res. 2021 Sep;35(9):5068-5102. doi: 10.1002/ptr.7137. Epub 2021 Apr 24.
Cardiovascular diseases (CVDs) are an ever-growing problem and are the most common cause of death worldwide. The uncontrolled production of reactive oxygen species (ROS) and the activation of ROS associated with various cell signaling pathways with oxidative cellular damage are the most common pathological conditions connected with CVDs including endothelial dysfunction, hypercontractility of vascular smooth muscle, cardiac hypertrophy and heart failure. The nuclear factor E2-related factor 2 (Nrf2) is a basic leucine zipper redox transcription factor, together with its negative regulator, kelch-like ECH-associated protein 1 (Keap1), which serves as a key regulator of cellular defense mechanisms to combat oxidative stress and associated diseases. Multiple lines of evidence described here support the cardiac protective property of Nrf2 in various experimental models of cardiac related disease conditions. In this review, we emphasized the molecular mechanisms of Nrf2 and described the detailed outline of current findings on the therapeutic possibilities of the Nrf2 activators specifically from herbal origin in various CVDs. Based on evidence from various preclinical experimental models, we have highlighted the activation of Nrf2 pathway as a budding therapeutic option for the prevention and treatment of CVDs, which needs further investigation and validation in the clinical settings.
心血管疾病(CVDs)是一个日益严重的问题,也是全球范围内最常见的死亡原因。活性氧(ROS)的不受控制的产生以及与各种细胞信号通路相关的 ROS 激活与氧化细胞损伤是与 CVDs 相关的最常见的病理状况,包括内皮功能障碍、血管平滑肌的过度收缩、心肌肥大和心力衰竭。核因子 E2 相关因子 2(Nrf2)是一种基本亮氨酸拉链氧化还原转录因子,与其负调节剂 Kelch 样 ECH 相关蛋白 1(Keap1)一起,作为细胞防御机制的关键调节剂,以对抗氧化应激和相关疾病。这里描述的多条证据支持 Nrf2 在各种与心脏相关的疾病模型中的心脏保护特性。在这篇综述中,我们强调了 Nrf2 的分子机制,并描述了目前关于 Nrf2 激活剂在各种 CVDs 中从草药来源的治疗可能性的详细研究结果。基于来自各种临床前实验模型的证据,我们强调了 Nrf2 途径的激活作为预防和治疗 CVDs 的潜在治疗选择,这需要在临床环境中进一步研究和验证。